As of 1:56:16 PM EST. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 1 | 2 | 2 |
| Avg. Estimate | -0.17 | -0.19 | -0.55 | -0.68 |
| Low Estimate | -0.17 | -0.19 | -0.55 | -0.8 |
| High Estimate | -0.17 | -0.19 | -0.55 | -0.56 |
| Year Ago EPS | -0.12 | -0.11 | -0.6 | -0.55 |
Revenue Estimate
| Currency in USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 1 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.15 | -0.15 | -0.13 | -0.18 |
| EPS Actual | -0.12 | -0.11 | -0.13 | -0.14 |
| Difference | 0.03 | 0.04 | 0 | 0.04 |
| Surprise % | 20.00% | 26.67% | 0.00% | 22.22% |
EPS Trend
| Currency in USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.17 | -0.19 | -0.55 | -0.68 |
| 7 Days Ago | -0.17 | -0.19 | -0.55 | -0.68 |
| 30 Days Ago | -0.17 | -0.19 | -0.55 | -0.68 |
| 60 Days Ago | -0.17 | -0.19 | -0.55 | -0.68 |
| 90 Days Ago | -0.17 | -0.19 | -0.55 | -0.68 |
EPS Revisions
| Currency in USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| AVXL | -41.67% | -72.73% | 8.33% | -23.64% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/27/2024 |
| Maintains | D. Boral Capital: Buy to Buy | 11/26/2024 |
| Maintains | D. Boral Capital: Buy to Buy | 11/25/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/4/2024 |
| Maintains | EF Hutton: Buy to Buy | 10/31/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 10/18/2024 |
Related Tickers
ANVS Annovis Bio, Inc.
5.14
-3.29%
SAVA Cassava Sciences, Inc.
2.7100
-1.45%
AXSM Axsome Therapeutics, Inc.
90.68
+0.64%
CGTX Cognition Therapeutics, Inc.
0.4620
-3.35%
GALT Galectin Therapeutics Inc.
2.2550
+6.87%
ALT Altimmune, Inc.
9.07
+0.44%
SLS SELLAS Life Sciences Group, Inc.
0.9444
+8.29%
CKPT Checkpoint Therapeutics, Inc.
3.3900
-7.63%
IOVA Iovance Biotherapeutics, Inc.
7.89
+0.77%
RVPH Reviva Pharmaceuticals Holdings, Inc.
2.5400
-2.68%